Northeast Financial Consultants’s Clearside Biomedical CLSD Stock Holding History

Northeast Financial Consultants’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$74.4K	Hold	6,200	–	–	﹤0.01%	294
2025 Q1	$85.4K	Hold	6,200	–	–	﹤0.01%	273
2024 Q4	$88.3K	Hold	6,200	–	–	﹤0.01%	282
2024 Q3	$118K	Hold	6,200	–	–	0.01%	284
2024 Q2	$121K	Hold	6,200	–	–	0.01%	263
2024 Q1	$142K	Hold	6,200	–	–	0.01%	281
2023 Q4	$109K	Buy	6,200 +667	+12%	+$9.51K	0.01%	272
2023 Q3	$72.2K	Hold	5,533	–	–	﹤0.01%	279
2023 Q2	$93K	Hold	5,533	–	–	0.01%	281
2023 Q1	$86.3K	Hold	5,533	–	–	0.01%	306
2022 Q4	$93K	Buy	5,533 +2,000	+57%	+$36K	0.01%	310
2022 Q3	$60K	Hold	3,533	–	–	﹤0.01%	328
2022 Q2	$78K	Hold	3,533	–	–	0.01%	320
2022 Q1	$121K	Hold	3,533	–	–	0.01%	375
2021 Q4	$146K	Buy	3,533 +2,666	+307%	+$173K	0.01%	343
2021 Q3	$78K	Buy	867 +200	+30%	+$17.7K	0.01%	348
2021 Q2	$49K	Hold	667	–	–	﹤0.01%	346
2021 Q1	$25K	Buy	+667	New	+$33.5K	﹤0.01%	329

Other funds holding CLSD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Northeast Financial Consultants's CLSD Position: Q2 2025 in Review

Northeast Financial Consultants held its Clearside Biomedical (CLSD) position steady in Q2 2025 at 6,200 shares worth $74.4K. The position accounts for ﹤0.01% of the portfolio, ranked #294.

Northeast Financial Consultants first reported a position in CLSD in Q1 2021 and has held it in 18 quarters since. The position peaked at $146K in Q4 2021. 44 funds tracked by Wall St. Rank hold CLSD as of Q2 2025.

Northeast Financial Consultants held 6,200 shares of Clearside Biomedical worth $74.4K as of Q2 2025.
Northeast Financial Consultants left its Clearside Biomedical share count unchanged in Q2 2025.
Clearside Biomedical made up ﹤0.01% of Northeast Financial Consultants's portfolio in Q2 2025, its #294 holding.
Northeast Financial Consultants first reported a position in Clearside Biomedical in Q1 2021 and has held it in 18 quarters since.
Northeast Financial Consultants's Clearside Biomedical position peaked at $146K in Q4 2021.
44 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2025.

Based on Northeast Financial Consultants's 13F filing for Q2 2025, filed 15 Aug 2025.